U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Hodgkin Lymphoma

MedGen UID:
155431
•Concept ID:
C0746341
•
Neoplastic Process
Synonym: Recurrent Hodgkin's Lymphoma

Definition

The reemergence of Hodgkin lymphoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.
Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, Talleur AC, Flerlage JE, Hudson MM, Metzger ML, Krasin MJ
Radiother Oncol 2019 May;134:89-95. Epub 2019 Feb 5 doi: 10.1016/j.radonc.2019.01.026. PMID: 31005229Free PMC Article
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS
Oncology (Williston Park) 2016 Dec 15;30(12):1099-103, 1106-8. PMID: 27987203Free PMC Article
Risk of breast cancer and breast cancer characteristics in women after treatment for Hodgkin lymphoma.
Wahner-Roedler DL, Petersen IA
Drugs Today (Barc) 2004 Oct;40(10):865-79. doi: 10.1358/dot.2004.40.10.863746. PMID: 15605120

Recent clinical studies

Therapy

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Diez-Martin JL, Corradini P, Michonneau D, Robinson S, Gutiérrez García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, El-Cheikh J, Ghesquières H, Montoto S, Dreger P, Sureda A
Cancer 2019 Jan 1;125(1):90-98. Epub 2018 Oct 23 doi: 10.1002/cncr.31755. PMID: 30351488
Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Bartlett NL
Hematology Am Soc Hematol Educ Program 2017 Dec 8;2017(1):317-323. doi: 10.1182/asheducation-2017.1.317. PMID: 29222273Free PMC Article
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL
Mol Imaging Biol 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9. PMID: 27798787
Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.
Pinto A, Corradini P, Mussetti A, Zinzani PL
Leuk Lymphoma 2015 Jul;56(7):1969-74. Epub 2014 Dec 4 doi: 10.3109/10428194.2014.981174. PMID: 25363402
Risk of breast cancer and breast cancer characteristics in women after treatment for Hodgkin lymphoma.
Wahner-Roedler DL, Petersen IA
Drugs Today (Barc) 2004 Oct;40(10):865-79. doi: 10.1358/dot.2004.40.10.863746. PMID: 15605120

Prognosis

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.
Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, Talleur AC, Flerlage JE, Hudson MM, Metzger ML, Krasin MJ
Radiother Oncol 2019 May;134:89-95. Epub 2019 Feb 5 doi: 10.1016/j.radonc.2019.01.026. PMID: 31005229Free PMC Article
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).
Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ
Biol Blood Marrow Transplant 2018 Apr;24(4):700-707. Epub 2017 Dec 28 doi: 10.1016/j.bbmt.2017.12.798. PMID: 29289757Free PMC Article
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL
Mol Imaging Biol 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9. PMID: 27798787
Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.
Pinto A, Corradini P, Mussetti A, Zinzani PL
Leuk Lymphoma 2015 Jul;56(7):1969-74. Epub 2014 Dec 4 doi: 10.3109/10428194.2014.981174. PMID: 25363402
Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces.
Huang Q, Wilczynski SP, Chang KL, Weiss LM
Am J Clin Pathol 2006 Aug;126(2):222-9. doi: 10.1309/DDGL-WRV3-KR91-64G7. PMID: 16891197

Clinical prediction guides

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.
Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, Talleur AC, Flerlage JE, Hudson MM, Metzger ML, Krasin MJ
Radiother Oncol 2019 May;134:89-95. Epub 2019 Feb 5 doi: 10.1016/j.radonc.2019.01.026. PMID: 31005229Free PMC Article
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).
Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ
Biol Blood Marrow Transplant 2018 Apr;24(4):700-707. Epub 2017 Dec 28 doi: 10.1016/j.bbmt.2017.12.798. PMID: 29289757Free PMC Article
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL
Mol Imaging Biol 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9. PMID: 27798787
Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation.
Dodero A, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F, Bramanti S, Frungillo N, Milani R, Crippa F, Fallanca F, Englaro E, Corradini P
Cancer 2010 Nov 1;116(21):5001-11. doi: 10.1002/cncr.25357. PMID: 20665491
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A
Cancer 2003 Jun 1;97(11):2748-59. doi: 10.1002/cncr.11414. PMID: 12767087

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...